US SEC Trading Suspension Halt Orders — March 02, 2026

02-03-2026

HCW Biologics Inc. (Nasdaq: HCWB) announced on March 2, 2026, that the Nasdaq Hearings Panel determined on February 26, 2026, the Company regained compliance with all continued listing rules for The Nasdaq Capital Market, avoiding delisting. This compliance enables continued access to public markets for capital to advance immunotherapies targeting autoimmune diseases, cancer, and senescence-associated diseases. CEO Dr. Hing C. Wong highlighted the Panel's discretion in providing time to meet the Equity Rule requirements.

• ·Phase 1 study for HCW9302 initiated in November 2025.
• ·Annual Report on Form 10-K filed with SEC on November 14, 2025.
• ·Two licensing agreements for exclusive worldwide rights to proprietary molecules.
• ·Pipeline details available at https://hcwbiologics.com/pipeline/

02-03-2026

Allurion Technologies, Inc. received a NYSE notice of delisting due to failure to maintain at least $50M in stockholders’ equity or 30-trading day average market capitalization, triggering potential delisting proceedings. The company intends to appeal the decision, expects shares to continue trading on NYSE during the appeal, and is executing a plan to regain compliance, catalyzed by FDA approval on February 20, 2026, an agreement with its largest creditor to exchange debt for preferred stock, and a warrant inducement on February 24, 2026. While efforts are ongoing, there is no guarantee of regaining compliance or relisting on NYSE or another exchange like NYSE American.

• ·Discussions and negotiations ongoing with existing creditors and security holders, plus capital raising efforts.
• ·Previous announcements: agreement with largest creditor for debt-to-preferred stock exchange at a substantial premium to current trading price (subject to conditions).
• ·SEC filings referenced: 10-K filed March 27, 2025 (amended August 19, 2025); 10-Q filed November 17, 2025.

02-03-2026

On March 2, 2026, My Size, Inc. received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), as the closing bid price fell below $1.00 for 30 consecutive business days. The company has 180 calendar days until August 31, 2026, to regain compliance by maintaining a $1.00 closing bid price for at least 10 consecutive business days, with potential for an additional 180 days if other listing standards are met. The Notification Letter has no immediate effect on trading, but failure to comply could lead to delisting proceedings, and the company may consider a reverse stock split.

• ·Trading symbol: MYSZ
• ·State of incorporation: Delaware
• ·Commission File Number: 001-37370
• ·IRS Employer Identification No.: 51-0394637
• ·Principal executive offices: HaNegev 4, POB 1026, Airport City, Israel 7010000
• ·Telephone: +972-3-600-9030

02-03-2026

Northann Corp. received NYSE American acceptance on February 24, 2026, of its compliance plan submitted by January 7, 2026, granting until June 8, 2027, to regain compliance with continued listing standards under Section 1003(a)(i) of the Company Guide. While the company's common stock (NCL, $0.001 par value) remains listed and traded with no immediate impact on operations or SEC reporting, failure to meet progress goals or full compliance by the deadline could trigger delisting proceedings. The company affirmed its intent to pursue all reasonable measures during this Plan Period, following an initial non-compliance notice on December 11, 2025.

• ·Initial non-compliance notice filed December 11, 2025
• ·Company is an emerging growth company
• ·Principal executive office: 2251 Catawba River Rd., Fort Lawn, SC 29714
• ·Trading symbol: NCL on NYSE American LLC

02-03-2026

On February 24, 2026, the Nasdaq Listing and Hearing Review Council affirmed the Nasdaq Hearings Panel's decision to delist Graphjet Technology's Class A ordinary shares due to failures under Listing Rules 5450(b)(2) (market value of listed securities) and 5450(b)(3)(C) (market value of publicly held shares), with delisting effective November 13, 2025. Despite the company's appeal on November 25, 2025, proposing compliance under Rule 5450(b)(1) with at least $10M stockholders' equity and $5M market value of publicly held shares, the decision was upheld with no path to reinstatement noted. This represents a significant negative development with no offsetting positive metrics.

• ·Trading suspended on Nasdaq on November 13, 2025.
• ·Panel delisting determination dated November 11, 2025.
• ·Appeal filed November 25, 2025 (Docket No. NQ 7187N-25), acknowledged November 26, 2025.
• ·Company incorporated in Cayman Islands; principal offices in Shah Alam, Selangor, Malaysia.
• ·Emerging growth company status confirmed.

02-03-2026

Iterum Therapeutics plc received a Nasdaq delisting determination on February 24, 2026, for noncompliance with the $1.00 minimum bid price rule and other standards including the $35M minimum market value of listed securities, shareholders' equity, and net income requirements. Ordinary shares face suspension from Nasdaq trading effective March 5, 2026, unless the company appeals to a hearings panel. The company is evaluating strategic alternatives, including potential wind-down, bankruptcy, or liquidation, where shareholders are unlikely to receive meaningful returns.

• ·Compliance period for Minimum MVLS Requirement extends until June 9, 2026.
• ·Nasdaq intends to file Form 25-NSE with SEC after appeal periods lapse.
• ·Company may file Form 15 to suspend reporting obligations post-delisting.